Vext Science Inc VEXTF

Beacon Securities Coverage

[empirestocks]

Vext Science has thus far flown under many radar screens, despite excellent fundamentals.  The company already generates 1st quartile performance, based on its opertaing cash flow and EBITDA margins for Q3/20.  Those results reflect only a partial contribution from the recent opening of a 2nd Phoenix-area dispensary, setting up sequential improvement in Q4/2020.

We understand the wholesale operation has 80%+ penetration of the staewide dispensary count (123 locations) and the cultivation/manufacturing expansion already underway should drive additional near-term growth, with completion expected in Q1/2021 (just as adult use doors could be opening).

We beleive these fundamentals make VEXT a very timely investment opportunity, through this window could be short lived. With several MSOs already active on the M&A front in Arizona, and others likely to join the hunt, we believe in Arizona, and others likely to join th ehunt, we believe VEXT could be a very attractive acquisition candidate that offers current cash flow and significant growth potential.

Buy rating $2.25/share

[askretka]

Thanks for posting that. I sold half my position into strength of training lately and my cost of rest is 0.15$ CDN. Will hold rest for awhile.

[lscfa]

What did they say about the constantly high accounts receivable?

[OPFunds]

Iscfa I am not sure what Beacon comments were on receivables, but Trickle Research has been covering Vext for the past year and they have a good grasp on Vext's receivables, I suggest you take a look. They have a few reports on Vext. Here is what they say about it in their last update https://www.trickleresearch.com/vext-science-inc/ First, to reiterate a theme that is threaded throughout